What’s the current market cap for Zevra Therapeutics stock?

Zevra Therapeutics (ZVRA) has a market cap of $605M as of May 21, 2026.

What is the P/E ratio for Zevra Therapeutics stock?

The price to earnings (P/E) ratio for Zevra Therapeutics (ZVRA) stock is 5.16 as of May 21, 2026.

Does Zevra Therapeutics stock pay dividends?

No, Zevra Therapeutics (ZVRA) stock does not pay dividends to its shareholders as of May 21, 2026.

When is the next Zevra Therapeutics dividend payment date?

Zevra Therapeutics (ZVRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Zevra Therapeutics?

Zevra Therapeutics (ZVRA) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Zevra Therapeutics stock | $ZVRA Share Price

13:30

15:10

16:45

18:25

20:00

About Zevra Therapeutics

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Ticker

$ZVRA

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Boston, United States

Website

www.zevra.com

ZVRA Metrics

BasicAdvanced

$605m

5.16

$1.98

0.88

What the Analysts think about ZVRA

Analyst ratings (Buy, Hold, Sell) for Zevra Therapeutics stock.

Bulls say / Bears say

Zevra reported Q2 2025 net revenue of $25.9 million, surpassing analyst expectations of $22.5 million, driven by strong MIPLYFFA sales and buoyed by a $150 million PRV sale, strengthening its financial position. (Reuters)

FY 2025 net revenue jumped to $106.5 million from $23.6 million in FY 2024, fueled by MIPLYFFA net sales of $87.4 million and highlighting rapid commercialization progress. (BioSpace)

As of December 31, 2025, Zevra held $238.9 million in cash, cash equivalents, and securities, providing ample resources to fund strategic initiatives without needing external financing. (BioSpace)

Q2 2025 operating loss was $71.0 million, masked by the one-time $150 million PRV sale, pointing to continued dependence on non-recurring gains rather than core operational profitability. (Reuters)

FY 2025 SG&A expenses increased to $77.6 million, up 41% from the previous year, reflecting higher commercialization costs that could pressure margins if revenue growth slows. (BioSpace)

The EMA’s Marketing Authorisation Application for arimoclomol received a 120-day list of questions, introducing regulatory uncertainty and the potential for delayed European market entry. (BioSpace)

Data summarised monthly by Lightyear AI. Last updated on 23 Apr 2026.

ZVRA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

ZVRA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZVRA

Capital at risk

Market open

Upcoming events

No upcoming events